Dimerix Limited ( (AU:DXB) ) just unveiled an announcement.
Dimerix Limited and Amicus Therapeutics have entered into an exclusive license agreement for the commercialization of Dimerix’s Phase 3 drug candidate DMX-200 in the United States. This agreement grants Amicus the rights to commercialize DMX-200 for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with no FDA-approved therapies, while Dimerix retains commercialization rights outside the U.S. The deal includes an upfront payment of US$30 million to Dimerix, with potential milestone payments and royalties based on sales and development achievements. This collaboration is expected to enhance Dimerix’s market positioning by leveraging Amicus’s regulatory and commercial expertise, potentially transforming treatment options for FSGS patients.
More about Dimerix Limited
Dimerix is a biopharmaceutical company focused on developing innovative therapies for areas with unmet medical needs. The company is headquartered in Victoria, Australia, and is involved in creating treatments for rare diseases, particularly in the field of nephrology.
YTD Price Performance: 41.18%
Average Trading Volume: 1,602,835
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$268.5M
For an in-depth examination of DXB stock, go to TipRanks’ Stock Analysis page.